Wedbush May Have Lost Confidence in Karyopharm Therapeutics (KPTI), Downgrades Shares

May 24, 2018 - By Marie Mckinney

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It worsened, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported.

Sg Americas Securities Limited Co stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). 69,928 were accumulated by Morgan Stanley. Baker Bros Advisors Lp, a New York-based fund reported 216,990 shares. First Personal Finance Service stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Moreover, Rhumbline Advisers has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). The Germany-based Deutsche Bank & Trust Ag has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). State Board Of Administration Of Florida Retirement Sys holds 0% or 14,761 shares in its portfolio. Point72 Asset Management Limited Partnership has invested 0.14% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Proshare Advsrs Ltd Liability Company stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). 4,600 are held by Amundi Pioneer Asset Mgmt. Northern Corporation reported 385,717 shares stake. Massachusetts-based Wellington Management Grp Llp has invested 0.01% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Geode Cap Ltd stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). State Common Retirement Fund holds 0% or 30,500 shares. Tekla Management Ltd Liability owns 20 shares for 0% of their portfolio.

Since December 11, 2017, it had 0 buys, and 31 selling transactions for $3.58 million activity. The insider Primiano Christopher Brett sold $37,527. The insider Shacham Sharon sold $91,553. Mirza Mansoor Raza also sold $42,525 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares.

Karyopharm Therapeutics (KPTI) Receives a Downgrade

Wedbush has cut Karyopharm Therapeutics (KPTI) shares to a “Neutral” in analysts note sent to investors this morning, while they’ve also set an estimated 12-month TP at $19.0. KPTI’s previous rating was a solid “Outperform”.

The stock decreased 9.02% or $1.72 during the last trading session, reaching $17.34. About 1.20 million shares traded or 46.14% up from the average. Karyopharm Therapeutics Inc. (KPTI) has risen 23.92% since May 25, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on August, 14. They expect $-0.73 EPS, down 14.06 % or $0.09 from last year’s $-0.64 per share. After $-0.78 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -6.41 % EPS growth.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.04 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Streetinsider.com which released: “Wedbush Downgrades Karyopharm Therapeutics (KPTI) to Neutral” on May 24, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on May 24, 2018, Benzinga.com published: “The Market In 5 Minutes: GE, Tariffs, Summit, Jobless Claims And More” on May 24, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay” published on May 02, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For May 24, 2018” with publication date: May 24, 2018.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.